| Q85362331 | Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol |
| Q38988427 | Co amorphous systems: A product development perspective |
| Q50998576 | Design of a novel type IV lipid-based delivery system for improved delivery of drugs with low partition coefficient. |
| Q85560544 | Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan |
| Q44293952 | Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: a case study with aceclofenac. |
| Q38564512 | Micellar carriers for the delivery of multiple therapeutic agents. |
| Q38730573 | Multidrug co-crystals: towards the development of effective therapeutic hybrids |
| Q39200489 | Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals. |
| Q39322457 | Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. |